|
Geron stock rises on promising stem cell research 2003-04-01 14:59:50 EST NEW YORK, April 1 (Reuters) - Shares of Geron Corp. rose as much as 40 percent on Tuesday after it published research indicating it could produce liver cells from stem cells in a way that could help scientists test drugs for liver toxicity. Shares of the Menlo Park, California-based company rose $1.11 to $6.40 in midafternoon trading on Nasdaq. Earlier they rose as high as $7.40. Geron showed in the journal Cell Transplantation how its scientists produce hepatocytes, the basic functional cells of the liver, from human embryonic stem cells. Hepatocytes have multiple characteristics, including the ability to metabolize enzymes. The scientists found that certain proteins found in liver cells are also expressed by those derived from the stem cells. The enzymes can be used to test whether a potential drug can be metabolized by the liver or whether it is toxic. If Geron`s method were successful it could allow scientists to reproduce large numbers of liver cells that would enable drug companies to test their drugs for toxicity much earlier in the development process - potentially cutting down the expense of taking drugs that are toxic through clinical trials. Last month the company`s shares rose $3 after the company said new researched showed its experimental cancer vaccine could be effective against all types of cancer. |
|
| aus der Diskussion: | Geron mit Hammernews!! |
| Autor (Datum des Eintrages): | meislo (02.04.03 20:59:07) |
| Beitrag: | 67 von 3,090 (ID:9065233) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |